Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Merck & Co., Inc. (NYSE:MRK) is one of the Best Dividend Leaders to Buy Now. Merck & Co., Inc. (NYSE:MRK) has struggled over ...

See the latest Merck & Co Inc stock price (MRK:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Merck & Co., Inc. (NYSE:MRK) is one of Best Dividend Stocks to Buy for Dependable Growth. Merck & Co., Inc. (NYSE:MRK) is one ...